These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 4056079)

  • 1. Comparison of two sustained-release theophylline preparations in adult patients with obstructive airways disease.
    Harkaway PS; Conlon PF; Hirsh JD; Allen WT
    J Clin Pharmacol; 1985 Sep; 25(6):444-7. PubMed ID: 4056079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
    Steinijans VW; Zech K; Fischer R
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of standard- and sustained-release theophylline tablets in patients with chronic obstructive pulmonary disease.
    Dasta J; Mirtallo JM; Altman M
    Am J Hosp Pharm; 1979 May; 36(5):613-7. PubMed ID: 453214
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of sustained-release theophylline ('Theo-dur') for the treatment of chronic reversible obstructive lung disease in hospital practice.
    Riddington CJ; Shipman AJ
    Br J Clin Pract; 1985 Apr; 39(4):148-53. PubMed ID: 3893504
    [No Abstract]   [Full Text] [Related]  

  • 5. Absorption of theophylline from conventional and sustained-release tablets.
    Fagerström PO; Mellstrand T; Svedmyr N
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis.
    Valet SB; Schwartz RH; Brooks JG
    Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption of theophylline from conventional and sustained-release tablets.
    Mellstrand T; Svedmyr N; Fagerström PO
    Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability.
    Rivera-Calimlim L; Calimlim JF; Liang R; Lasagna L; Diamond GL
    J Asthma; 1986; 23(3):113-22. PubMed ID: 3528119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Time-related distribution of delayed-action theophylline in the treatment of chronic obstructive bronchopneumopathies].
    Philip-Joet F; Bruguerolle B; Parrel M; Vestri R; Arnaud A
    Presse Med; 1988 Feb; 17(5):193-6. PubMed ID: 2965374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption properties of two theophylline sustained-release products in smokers.
    Miller R; Rheeders M
    S Afr Med J; 1984 Jun; 65(26):1045-8. PubMed ID: 6740419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of once-daily Uniphyl tablets compared with twice-daily Theo-Dur tablets in elderly patients with chronic airflow obstruction.
    Rivington RN; Calcutt L; Hodder RV; Stewart JH; Aitken TL
    Am J Med; 1988 Jul; 85(1B):48-53. PubMed ID: 3041826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic obstructive pulmonary disease with two sustained-release theophylline preparations.
    Giosue S; Bernocchi D; Parola D; Munno R; Mancini P
    J Int Med Res; 1987; 15(6):352-60. PubMed ID: 3325318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods of comparing pharmacokinetics of slow release preparations: a comparison of "Theo-Dur" and "Phyllocontin" in patients with asthma.
    Jackson SH; Shah K; Turner P
    Eur J Clin Pharmacol; 1986; 30(3):313-7. PubMed ID: 3732367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans.
    Raz I; Bialer M; Salame K; Bar-On H
    Eur J Clin Pharmacol; 1984; 26(3):401-3. PubMed ID: 6734702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma theophylline concentrations in patients with chronic obstructive airways disease after administration of a new sustained release theophylline formulation.
    Taylor DR; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1982 Apr; 13(4):569-71. PubMed ID: 7066172
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biological availability of two theophylline preparations (author's transl)].
    Kaik G
    Prax Klin Pneumol; 1982 Jun; 36(6):294-6. PubMed ID: 7111181
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum theophylline levels with oral sustained release theophylline after transfer from intravenous aminophylline in patients with chronic lung disease.
    Silins RA; Butcher MA; Marlin GE
    Br J Clin Pharmacol; 1984 Oct; 18(4):645-7. PubMed ID: 6487509
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum drug fluctuations after administration of two sustained-release oral theophylline preparations in asthmatic children.
    Logvinoff MM; Weinstein DB; Watts MT; Seifert B
    Clin Ther; 1986; 8(2):175-80. PubMed ID: 3698064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Optimizing therapy with theophylline preparations in obstructive ventilation disorders. 3. Prediction of theophylline clearance with a simple pharmacokinetic method and comparison of bioavailability of various theophylline retard preparations].
    Ranke C; Schmidt G; Oellerich M; Sybrecht GW
    Prax Klin Pneumol; 1983 Mar; 37(3):99-108. PubMed ID: 6856564
    [No Abstract]   [Full Text] [Related]  

  • 20. [Possibilities for optimizing therapy with theophylline preparations. I. On the pharmacokinetics of theophylline preparations].
    Wiesner B; Sehrt I; Iwainsky H
    Z Erkr Atmungsorgane; 1984; 162(1):3-10. PubMed ID: 6719957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.